JSB Market Research: Nuclear Medicine Market and Radiopharmaceuticals - Global Trends & Forecast to 2017
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
($Million)<br />
Table 90 North America: Spect Radiopharmaceutical <strong>Market</strong>, By Iso<strong>to</strong>pe, 2010 – <strong>2017</strong><br />
($Million)<br />
Table<br />
List of Figures<br />
Figure 1 <strong>Global</strong> Radiopharmaceutical <strong>Market</strong>, By Segment, 2010 – <strong>2017</strong><br />
Figure 2 <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Geography, 2012 ($Million)<br />
Figure 3 <strong>Global</strong> Stable Iso<strong>to</strong>pes <strong>Market</strong>, 2012 – <strong>2017</strong> ($Million)<br />
Figure 4 Evolution Of <strong>Radiopharmaceuticals</strong><br />
Figure 5 <strong>Radiopharmaceuticals</strong> <strong>Market</strong> Segmentation<br />
Figure 6 Enriched Stable Iso<strong>to</strong>pes <strong>Market</strong> Segmentation<br />
Figure 7 <strong>Market</strong> Dynamics<br />
Figure 8 <strong>Radiopharmaceuticals</strong>: <strong>Market</strong> Share Analysis, By Key Players, 2012<br />
Figure 9 Enriched Stable Iso<strong>to</strong>pe: <strong>Market</strong> Share Analysis, By Key Players, 2012<br />
Figure 10 Mo-99/Tc-99m: Supply Chain<br />
Figure 11 Tc-99m: Supply Chain Participants<br />
Figure 12 Tc-99m: Value Chain Analysis<br />
Figure 13 Tc-99m: Pricing Fac<strong>to</strong>rs<br />
Figure 14 Fluorine-18: Supply Chain<br />
Figure 15 Deuterium: Supply Chain<br />
Figure 16 Major Sponsors, Clinical Studies, 2010 – <strong>2017</strong><br />
Figure 17 Clinical Trials For Diagnostic & Therapeutic Applications Of Radioiso<strong>to</strong>pes, By<br />
Phase, 2010 – <strong>2017</strong><br />
Figure 18 Clinical Trials (Phase Iii & Iv) For Diagnostic Radioiso<strong>to</strong>pes, 2010 – <strong>2017</strong><br />
Figure 19 Upcoming Radiopharmaceutical Applications (Diagnosis), 2010 – <strong>2017</strong><br />
Figure 20 Clinical Trials (Phase Iii & Iv) For Therapeutic Radioiso<strong>to</strong>pes, 2010 – <strong>2017</strong><br />
Figure 21 Upcoming Radiopharmaceutical Applications (Therapy), 2010 – <strong>2017</strong><br />
Figure 22 Mo-99 Dem<strong>and</strong> (Six Days Curie) Per Week, 2012 Vs 2030<br />
Figure 23 Mo-99: Supply Vs Dem<strong>and</strong> Analysis, 2010 – 2020<br />
Figure 24 Shift Towards Leu From Heu<br />
Figure 25 Sustainable Supply Chain & Logistics<br />
Figure 26 Opportunity Matrix: <strong>Global</strong> Diagnostic <strong>Radiopharmaceuticals</strong> <strong>Market</strong> (2012)<br />
Figure 27 Spect Radioiso<strong>to</strong>pe <strong>Market</strong> Share (2012)<br />
Figure 28 Pet <strong>Radiopharmaceuticals</strong> <strong>Market</strong> Share (2012)<br />
Figure 29 Opportunity Matrix: <strong>Global</strong> Therapeutic <strong>Radiopharmaceuticals</strong> <strong>Market</strong> (2012)<br />
Figure 30 Ra-223 Decay Chain<br />
Figure 31 Porter’s Five Forces Analysis For Alpharadin<br />
Figure 32 Swot Analysis Of Alpharadin<br />
Figure 33 <strong>Global</strong> Radiopharmaceutical Procedures <strong>Market</strong>, 2012<br />
Figure 34 Diagnostic <strong>Radiopharmaceuticals</strong> <strong>Market</strong>, By Indication (2012)<br />
Email ID- contact@jsbmarketresearch.com<br />
Tel No- 91 2241236650<br />
Published by- http:/www.jsbmarketresearch.com/